Contravir Pharmaceuticals Inc., of Edison, N.J., closed a private placement of series A convertible preferred shares to an undisclosed ex-U.S. investor for gross proceeds of $9 million. The preferred shares may be converted at any time into common shares at a rate of 48 cents apiece, but Contravir said the investor agreed to lock up the preferred and underlying common shares until April 14, 2016.